Table 3.
Multivariate analysis for patients with TNBC.
| Relapse-free survival | Overall survival | ||||
|---|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | ||
| VISTA on ICs | 0.158 | 0.012 | |||
| Negative | 1 | 1 | |||
| Positive | 0.698 (0.423–1.151) | 0.436 (0.228–0.831) | |||
| Age | 0.999 | 0.709 | |||
| < 50 years | 1 | 1 | |||
| ≥ 50 years | 1.000 (0.619–1.615) | 1.119 (0.620–2.019) | |||
| AJCC stage | <0.001 | 0.001 | |||
| I | 1 | 1 | |||
| II | 1.884 (0.959–3.703) | 0.066 | 2.181 (0.863–5.508) | 0.099 | |
| III | 4.182 (2.066–8.466) | <0.001 | 5.217 (2.068–13.164) | <0.001 | |
| Ki 67 | 0.2 | 0.366 | |||
| < 14% | 1 | 1 | |||
| ≥ 14% | 1.683 (0.760–3.727) | 1.549 (0.600–3.996) | |||
| Differentiation | 0.922 | 0.951 | |||
| Moderate+Well | 1 | 1 | |||
| Poor | 1.028 (0.594–1.777) | 1.021 (0.522–1.996) | |||
TNBC, triple-negative breast cancer; VISTA, V-domain Ig suppressor of T-cell activation; IC, immune cell; AJCC, American Joint Committee on Cancer; CI, confidence interval.